NCT03502681 - A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

October 25, 2019

Study Completion Date

October 25, 2019

Conditions

Metastatic Urothelial Cell Cancer

Interventions

DRUG

Eribulin Mesylate

"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m\^2;~Dose level 0: 1.1 mg/m\^2;~Dose level +1: 1.4 mg/m\^2"

DRUG

Avelumab

Days 1, 15 Avelumab (10mg/kg)

Trial Locations (2)

Penn State Cancer Intsitute, Hershey

Univeristy of Iowa Hospital and Clinics, Iowa City